Corcept Therapeutics(CH:HTD)
CH:HTD
Corcept Therapeutics financials statements
Corcept Therapeutics (HTD) Income Statement
0 Followers
Corcept Therapeutics Income Statement
Last quarter (Q3 2026), Corcept Therapeutics's total revenue was $340.47M, an increase of 63.97% from the same quarter last year. In Q3, Corcept Therapeutics's net income was $126.78M. See Corcept Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 761.41M | $ 675.04M | $ 482.38M | $ 401.86M | $ 365.98M | |
| $ 748.43M | $ 664.16M | $ 475.89M | $ 396.47M | $ 360.70M | |
| $ 703.63M | $ 527.21M | $ 368.61M | $ 283.84M | $ 236.22M | |
| Depreciation and Amortization | $ 1.89M | $ 1.34M | $ 2.36M | $ 3.45M | $ 3.07M |
| $ 68.35M | $ 162.83M | $ 126.92M | $ 119.64M | $ 127.95M | |
| $ 44.80M | $ 136.95M | $ 107.28M | $ 112.63M | $ 124.48M | |
| $ 21.67M | $ 24.54M | $ 17.27M | $ 3.56M | $ 529.00K | |
| $ 66.46M | $ 161.49M | $ 124.56M | $ 116.19M | $ 125.01M | |
| $ 99.65M | $ 139.73M | $ 106.14M | $ 101.42M | $ 112.51M | |
| Per Share Metrics | |||||
| Basic EPS | $ 0.95 | $ 1.35 | $ 1.02 | $ 0.95 | $ 0.97 |
| Diluted EPS | $ 0.82 | $ 1.23 | $ 0.94 | $ 0.87 | $ 0.89 |
| Weighted Average Shares Outstanding | 103.86M | 103.23M | 103.56M | 106.79M | 115.65M |
| Weighted Average Shares Outstanding (Diluted) | 119.99M | 113.48M | 111.74M | 115.97M | 125.96M |
Currency in USD
